CRANBURY, N.J., Nov. 2, 2026 - Accutar Biotechnology, Inc., a clinical-stage biotechnology company focused on artificial intelligence (AI)-empowered drug discovery, today announced the achievement of a preclinical development milestone in its multi-year, multi-target research collaboration with Evommune, Inc. (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases.